This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study. Issue 190 (June 2020)
Record Type:
Journal Article
Title:
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study. Issue 190 (June 2020)
Main Title:
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study
Highlights: This was a randomized, single-blind, cross-over study in Chinese patients. Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel. 60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.